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Background: Prostate cancer is the most common male malignancy and a mayor cause of mortality in the western
world. The impact of clinicopathological variables on disease related outcomes have mainly been reported from a
few large US series, most of them not reporting on perineural infiltration. We therefore wanted to investigate
relevant cancer outcomes in patients undergoing radical prostatectomy in two Norwegian health regions with an
emphasis on the impact of perineural infiltration (PNI) and prostate specific antigen- doubling time (PSA-DT).
Methods: We conducted a retrospective analysis of 535 prostatectomy patients at three hospitals between 1995
and 2005 estimating biochemical failure- (BFFS), clinical failure- (CFFS) and prostate cancer death-free survival
(PCDFS) with the Kaplan-Meier method. We investigated clinicopathological factors influencing risk of events using
cox proportional hazard regression.
Results: After a median follow-up of 89 months, 170 patients (32%) experienced biochemical failure (BF), 36 (7%)
experienced clinical failure and 15 (3%) had died of prostate cancer. pT-Stage (p = 0.001), preoperative PSA (p = 0.047),
Gleason Score (p = 0.032), non-apical positive surgical margins (PSM) (p = 0.003) and apical PSM (p = 0.031) were all
independently associated to BFFS. Gleason score (p = 0.019), PNI (p = 0.012) and non-apical PSM (p = 0.002) were all
independently associated to CFFS while only PNI (P = 0.047) and subgroups of Gleason score were independently
associated to PCDFS. After BF, patients with a shorter PSA-DT had independent and significant worse event-free
survivals than patients with PSA-DT > 15 months (PSA-DT = 3-9 months, CFFS HR = 6.44, p < 0.001, PCDFS HR = 13.7,
p = 0.020; PSA-DT < 3 months, CFFS HR = 11.2, p < 0.001, PCDFS HR = 27.5, p = 0.006).
Conclusions: After prostatectomy, CFFS and PCDFS are variable, but both are strongly associated to Gleason score and
PNI. In patients with BF, PSA-DT was most strongly associated to CF and PCD. Our study adds weight to the importance
of PSA-DT and re-launches PNI as a strong prognosticator for clinically relevant endpoints.* Correspondence: sigve.andersen@uit.no
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Prostate cancer (PC) is the most common male malig-
nancy and the second most common cause of cancer
mortality in Norway [1]. It is presently the most preva-
lent cancer and there has been an increasing incidence
until 2007 where after a reduction was noted [1]. When
PSA was widely introduced in Norway in the early
1990s, an increasing number of men were diagnosed
and treated with curative intent (33% in 2001) [2]. Al-
though declining, Norway has the highest mortality rate
of all western countries [3,4]. There has been an increasing
use of radical prostatectomy (RP), but a majority of pa-
tients diagnosed with PC will not have symptomatic dis-
ease or die of the disease as they have non-lethal P [5].
The reduced risk of prostate cancer specific mortality
after a radical prostatectomy compared to watchful
waiting has been estimated to range between 0-25% de-
pending on tumor characteristics [6]. The only RCT evi-
dence for a reduction in prostate cancer mortality is the
SPCG-4 trial [7].
Disease-specific survival after RP has mainly been re-
ported from a number of single institutions, but a few
studies have reported on larger cohorts and three stud-
ies have described survival in nationwide cohorts in
Europe [8-10]. Some of these larger studies lack suffi-
cient follow-up, relevant prognostic parameters and
clinically relevant end-points in the analysis.
Clinicopathological variables for predicting disease
outcome after RP are numerous with Gleason grade
and score, pTNM-stage, preoperative PSA and surgical
margins as the most widely adopted ones [11,12]. User-
friendly predictive tools like look-up tables, risk classifica-
tions and nomograms have been developed [11,13]. Some
variables like lymphovascular invasion [14], tumor volume
[15], pT2 subclassification [16] and tertiary Gleason
grade [17] are conflicting or have insufficient support-
ing data yet.
For patients with biochemical failure (BF) there are
several treatment options including continuous, inter-
mittent or deferred androgen deprivation, salvage ir-
radiation of the prostate bed and trial participation. To
choose the optimal therapy for these patients it is cru-
cial to understand the risk factors for a subsequent
clinical failure or death of PC, especially since manage-
ment strategy remains controversial [18-20]. After BF,
PSA kinetics, or more specifically PSA-Doubling Time
(PSA-DT), has emerged as a prognostic variable [21-25].
However, as a pretreatment marker, PSA-DT has not
found its position [26,27].
The objective of the present study was to describe dis-
ease outcome data for patients operated in the PSA era in
three urological centers in two major health regions in
Norway, and to examine the impact of post-prostatectomy
PSA-DT on clinical outcomes.Methods
Patients
671 patients were retrospectively identified with RPs for
adenocarcinoma of the prostate between 01.01.1995 to
31.12.2005 from the archives of the Departments of
Pathology at St. Olav Hospital/Trondheim University
Hospital (St. Olav) (n = 341), Nordlandssykehuset Bodo
(NLSH) (n = 63) and the University Hospital of Northern
Norway (UNN) (n = 267). Of these, 131 patients were ex-
cluded due to non-available tissue blocks for re-evaluation
(St. Olav n = 112, NLSH n = 3, UNN n = 15), four patients
were excluded due to other cancers (not superficial skin
cancers) within 5 years of diagnosis (UNN n = 4), one pa-
tient was excluded due to previous radiotherapy to the
pelvic region (NLSH) and one patient due to lack of follow-
up data (St. Olav). Thus, 535 eligible patients had complete
follow-up data and tissue blocks for re-evaluation. Pre-
operative clinical TNM staging was unevenly stated in the
medical files and data are therefore not presented.
Definition of end-points and clinical variables
The preoperative PSA values were assessed right before
surgery, except for those few patients who underwent
transurethral resection of the prostate (TUR-P) prior to
the RP. For these patients the PSA value before the TUR-P
was used. PC was an incidental finding in these patients.
BF was defined as PSA ≥0.4 ng/ml in at least two
consecutive postoperative blood samples according to
Stephenson et al. [28]. Clinical failure (CF) was defined
as verified symptomatic locally advanced progression after
radical treatments and/or metastasis to bone, visceral
organs or lymph nodes on CT, MR, bone scan or ultra-
sonography. Prostate cancer death (PCD) was defined
as death with progressive and disseminated castration-
resistant PC despite therapy. PSA-DT was calculated
by the online available MSKCC-calculator (http://nomo-
grams.mskcc.org/Prostate/PsaDoublingTime.aspx) which
calculates a regression slope on the basis of all PSA values
taken using natural log of 2 (0.693) divided by the slope of
the relationship between the log of PSA and time of PSA
measurement for each patient in months [24]. Up to four
separate (at least 6 weeks apart) PSA measurements before
supplementary treatment (endocrine therapy, radiotherapy
or chemotherapy) were included. Optimal cut-off points
for stratification of PSA-DT have been varying between
reporters. We used cut-off values as the largest reported
patient series to date from Johns Hopkins [21]. Hence,
the four groups of patients with significantly differing prog-
nosis for both CF and PCD were patients with PSA-DT <
3 months, 3–9 months, 9–15 months and >15 months.
Postoperative follow-up (FU) protocols were not com-
pletely uniform in the participating hospitals, but all FUs
included PSA measurements and clinical examinations
(including digital rectal examination in PSA recurrence)
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the second year and once yearly for the following years.
Imaging with CT, MRI or radio nucleotide bone scans was
done upon symptoms or rising PSA.
The follow-up of patients was done by examining the pa-
tient medical files at the operating centers and the patients’
local hospital. Biochemical failure free survival (BFFS) was
calculated from the date of surgery to the last FU date for
BF, which was the last date of a measured PSA. Clinical fail-
ure free survival (CFFS) was calculated from the date of
surgery to the last FU date for CF, which was the last date
without symptoms or any evidence of metastasis. Prostate
cancer death free survival (PCDFS) was calculated from the
date of surgery to the date of death.
Tissues
All prostate specimens were re-evaluated regarding to
histopathological variables and re-staged according to
the 2010 revision of the TNM classification [29] inde-
pendently by two experienced pathologists (E.R, L.T.B).
A positive surgical margin (PSM) was defined as tumor
extension to the inked surface of the resected specimen
[30-32]. Tumor size was measured as the largest diam-
eter of the index tumor and was used due to previous
observations of excellent correlation to PC volume [15].
Median tumor size was 20 mm and was set as cut-off in
further analyses. Perineural infiltration (PNI) was de-
fined as tumor cells within the perineural space adjacent
to a nerve outside of the prostate capsule. Lymphovascu-
lar infiltration (LVI) was defined as tumor cells found
within lymphatic or blood vessels. Gleason grading was
re-graded according to the 2005 International Society of
Urological Pathology Modified Gleason System [33].
Statistical methods
Analyses for the patients with BF regarding the impact
of PSA-DT on CFFS and PCDFS required the baseline
date to be changed to date of BF as opposed to date of
surgery for the other analyses.
The SPSS version 20 was used for the statistical analyses
(Chicago, IL. USA). The non-parametric Spearman correl-
ation coefficient (r) was used to calculate correlations be-
tween variables and only moderate or strong correlations
(r > 0.3) are described. χ2 statistics were utilized for distri-
bution differences between groups. Plots of the event-free
survivals were drawn using the Kaplan-Meier method, and
the statistical significance between survival curves was
assessed by the log-rank test. Univariate analyses for the
various endpoints (Table 1) according to clinical and
histopathological variables were done. Significant variables
(bold text in Table 1) were entered in the multivariate ana-
lyses for all patients (Table 2). The backward Cox regres-
sion analysis was used with a probability for stepwise entry
and removal at 0.05 and 0.10, respectively. A p-value < 0.05was considered statistically significant for all analyses. For
the patients with BF (Table 3), all significant variables from
the univariate analyses for both CF and PCD, were entered
in the multivariate analysis These were tumor size, the
margin variables, PNI, LVI, pT stage, pN stage and Glea-
son score. Due to the low number of events for PCD (15
events) we used an enter model with manual inclusion
and removal of variables to identify the three most signifi-
cant variables (Gleason score, PNI and positive non-apical
margin) before entering them into the models.
Ethics
This study was approved by the regional ethics commit-
tee, REK Nord, project application 2009/1393.
Results
Patient characteristics
Median age at surgery was 62 years (range 45–75), median
follow-up of survivors was 89 months (range 6.3-188.3).
279 patients underwent a limited lymphadenectomy.
The pT2 group (n = 374) was sub-classified to pT2a
(n = 139; 37%), pT2b (n = 34; 9%) and pT2c (n = 201;
54%). pT stage was correlated to PNI (r = 0.33, p <
0.001), T-Size (r = 0.30, p < 0.001) and positive non-
apical margin (r = 0.373 p < 0.001).
Indications for lymph node dissection were not predeter-
mined for the centers involved, but was done according to
the surgeons preference which mostly was if Partin nomo-
grams indicated >10% risk of N1 disease or Gleason ≥8,
PSA ≥10 or suspected cT3. Three patients were found to
have discrete metastasis in regional lymph nodes at re-
evaluation (paraffin embedded tissue) of initial frozen-
section-negative lymph nodes.
Preoperative PSA was available for 542 of 548 (99%) pa-
tients. Median value was 8.8 ng/ml (range 0.7-104.3). The
variable was dichotomized with PSA = 10 ng/ml as chosen
cut-off.
Distributions of Gleason scores are presented in Table 1.
Patients with Gleason 4 + 5 (n = 26; 5%), Gleason 5 + 4 (n =
6; 1%) and Gleason 5 + 5 (n = 3, <1%) were pooled in the
Gleason ≥9 group due to the low number of these patients.
In patients with BF, Gleason score correlated inversely with
PSA-DT (r = −0.37, p <0.001)
The maximum diameter of the index tumor (T-Size)
had a median value of 20 mm (range 2–50). T-Size cor-
related significantly with pT stage (r = 0.30 p < 0.001).
We explored the prognostic value of T-Size in the pT2
subgroup, but no significant association to event-free-
survival was found in univariate analyses and the vari-
able was consequently not entered into multivariate
analysis.
PNI correlated to LVI (r = 0.393, p < 0.001), and pT stage
(r = 0.33, p < 0.001 77 (14%) patients of the patients had
both apical and non-apical PSM. There was a significant
Table 1 Patient characteristics and clinicopathological variables, and their prognostic value for the three endpoints in
535 prostate cancer patients (univariate analyses; log rank test)
Characteristic Patients Patients BF CF PCD
(n) (%) (170 events) (36 events) (15 events)
5-year EFS (%) p 10-year EFS (%) p 10-year EFS (%) p
Age 0.55 0.085 0.600
≤ 65 years 357 67 76 92 97
> 65 years 178 33 70 88 96
pT-stage <0.001 <0.001 0.027
pT2 374 70 83 96 98
pT3a 114 21 60 86 98
pT3b 47 9 43 73 89
pN-stage <0.001 <0.001 <0.001
NX 264 49 79 95 98
N0 268 50 71 89 97
N1 3 1 0 33 67
Preop PSA <0.001 0.085 0.061
PSA < 10 308 57 80 93 99
PSA > 10 221 42 67 88 95
Missing 6 1 - - -
Gleason <0.001 <0.001 0.001
3 + 3 183 34 83 98 99
3 + 4 220 41 76 93 98
4 + 3 80 15 69 84 95
4 + 4 19 4 63 76 94
≥9 33 6 34 67 87
Tumor size <0.001 0.019 0.098
0-20 mm 250 47 82 94 99
>20 mm 285 53 67 88 96
PNI <0.001 <0.001 0.002
No 401 75 79 95 98
Yes 134 25 60 81 93
PSM 0.041 0.038 0.697
No 249 47 81 94 97
Yes 286 53 69 89 97
Non-apical PSM <0.001 <0.001 0.029
No 381 71 81 95 98
Yes 154 29 57 81 94
Apical PSM 0.04 0.484 0.31
No 325 61 73 90 96
Yes 210 39 77 92 98
LVI <0.001 <0.001 0.009
No 492 92 77 93 98
Yes 43 8 46 71 88
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Table 1 Patient characteristics and clinicopathological variables, and their prognostic value for the three endpoints in
535 prostate cancer patients (univariate analyses; log rank test) (Continued)
Surgical proc 0.23 0.41 0.581
Retropubic 435 81 76 90 97
Perineal 100 19 67 95 98
Abbreviations: BF biochemical failure, CF Clinical failure, EFS event free survival in months, LVI lymphovascular infiltration, PCD prostate cancer death, NR not
reached, P P value for log rank statistic for difference in event free survival, PC Prostate cancer, PNI Perineural infiltration, Post op RT postoperative radiotherapy,
Preop preoperative, PSA Prostate specific antigen, PSM Positive surgical margin, Surgical proc surgical procedure. Significant p-values in bold (threshold p ≤ 0.05).
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of the period (χ2, p < 0.001). During the period 1995–2000
129/197 (66%) patients had PSM while in the period
2001–2005 162/351 (46%) patients had PSM. LVI corre-
lated with PNI and to pT stage (r = 0.33, p < 0.001.
In pT3 patients, 109 of 161 (68%) patients had PSM
while 182 of 387 (47%) pT2 patients had PSM. ThereTable 2 Multivariate analyses in models including significant
(Cox regression, backward conditional)
Characteristic BF (170 events)†
HR CI95% p HR
pT-stage 0.001 NS
pT2 1
pT3a 1.70 1.14-2.54 0.010
pT3b 2.40 1.45-3.97 0.001
Preop PSA NE
PSA < 10 1
PSA > 10 1.39 1.01-1.91 0.047
Gleason 0.032
3 + 3 1 1
3 + 4 1.05 0.70-1.56 0.81 2.45
4 + 3 1.55 0.97-2.47 0.07 2.87
4 + 4 1.42 0.68-2.97 0.36 2.73
≥9 2.39 1.31-4.35 0.004 6.74
PNI 0.090
No 1 1
Yes 1.35 0.95-1.92 2.48
Non-apical PSM± 0.003
No 1 1
Yes 1.70 1.20-2.40 3.22
Apical PSM± 0.031 NE
No 1
Yes 0.69 0.49-0.97
Significant p-values in bold (threshold p ≤ 0.05).
Abbreviations: BF biochemical failure, CF Clinical failure, LVI lymphovascular infiltratio
significant, the characteristic is removed by the backward conditional analysis due
RT postoperative radiotherapy, Preop preoperative, PSA Prostate specific antigen, PS
†Tumor Size, pN-stage and LVI were removed by the backward conditional model d
±Only the subgroups (apical/non-apical PSM) of PSM were entered.
*Due to the low number of events the model was carefully analyzed in advance wi
significant in advance before doing the final model with the three variables; Gleasowas a significant association with operating center (χ2,
p < 0.001) with St. Olav having the lowest PSM rates.
In non-apical PSM, PSA correlated significantly with
pT stage (r = 0.373, p < 0.001).
When stratifying for pT stage non-apical PSM had a
significant impact in pT3a patients (p = 0.001), but not
in pT2 (p = 0.69) or pT3b patients (p = 0.075).univariate analyses for all patients
CF (36 events) PCD (15 events)*





0.78-6.90 0.09 3.71 0.41-33.2 0.242
0.91-9.10 0.07 10.47 1.21-90.7 0.033
0.52-14.2 0.23 7.43 0.46-121 0.159







n, NE not entered, due to non-significance in the univariate analyses, NS not
to insignificance, PCD prostate cancer death, PNI Perineural infiltration, Post op
M Positive surgical margin.
ue to insignificance in all models.
th the inclusion and removal of variables in an enter analysis to find the most
n score, perineural infiltration and positive non-apical margin.
Table 3 Multivariate analysis including significant univariate analyses for the 170 patients with biochemical failure
(Cox regression, backward conditional)
Patients CF (36 events)† PCD (15 events)*
N (%) 5-year EFS (%) HR CI95% p Events (N) 10-year EFS (%) HR CI95% p Events (N)
PSA-DT <0.001 0.029
Missing 12 7 - NE 3 - NE 0
>15 71 42 98 1 Ref 5 93 1 Ref 1
9-14.9 27 16 77 3.28 0.9-11.9 0.09 5 86 4.60 0.41-52.0 0.22 2
3-8,9 46 27 69 6.44 2.26-18.3 <0.001 16 70 13.7 1.51-124 0.020 8
<3 14 8 59 11.2 3.35-37.7 <0.001 7 49 27.5 2.64-286 0.006 4
pN-stage 0.002 0.020
NX 69 41 1 Ref 9 1 Ref 3
N0 98 57 1.38 0.61-3.13 0.45 24 1.20 0.31-4.59 0.80 11
N1 3 2 19.1 3.69-100 <0.001 2 32.5 2.61-405 0.007 1
Significant p-values in bold (threshold p ≤ 0.05).
Abbreviations: BF biochemical failure, CF Clinical failure, NS not significant, the characteristic is removed by the backward conditional analysis due to insignificance,
NE not entered, PCD prostate cancer death, PSA Prostate specific antigen, PSA-DT PSA doubling time in months; †a positive non-apical margin, PNI, vasc inf, pT
stage and Gleason were removed by the backward conditional model due to insignificance in all models. *Due to the low number of events the model was
carefully analyzed in advance with the inclusion and removal of variables in an enter analysis to find the most significant in advance before doing the final model
with the three variables; PSA-DT, Gleason score and pN-stage.
Figure 1 Overlapping Kaplan-Meier curves, each illustrating
event-free survival for the whole cohort for the specific event.
Note that the Y-axis has been modified with a proportion of 0.5 as
the origin to better illustrate the differences. PCDF-survival = Prostate
cancer death free-survival; CFF-survival = Clinical failure free-survival;
BFF = Biochemical failure free-survival.
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170 patients had BF during FU. Of these, 31 patients never
reached postoperative PSA nadir < 0.4 ng/ml. When re-
moving these patients (143 patients left) the median time
to BF was 35 months (range 2.8-164). For CF patients the
median time from BF to CF was 38.2 months (range 0–
130.7). For PCD patients the median time from BF to
PCD was 72.2 months (range 34.4-147). Kaplan-Meier
curves illustrates event-free survivals are in Figure 1.
PSA data before salvage therapy was retrievable for 158
out of 170 patients with BF to calculate PSA-DT. Median
PSA-DT was 13.6 months (range 0.4-332). Quartile cut-off
values were 5.5, 13.4, and 23.9 months. We used the previ-
ously published cut-offs regarding PSA-DT [21] as these in
our cohort reliably divided the patients into subgroups with
differing hazard ratios for CF or PCD. PSA-DT correlated
inversely with Gleason score (r = −0.37, p < 0.001) (Figure 2).
Kaplan-Meier curves illustrating event-free survivals ac-
cording to different PSA doubling times are in Figure 2.
For validation we did subgroup analyses stratifying for
health regions. The results were highly significant in both
Helse Nord (p < 0.001) and Helse Midt (p = 0.004).
Among the 36 (7%) patients with CF, 13 patients had
symptomatic locally advanced progression, 18 had bone
metastasis and 5 had regional lymph node metastasis. Me-
dian time to CF after RP was 64 months (range 15–159).
Concerning CF, 8/33 events (24%) were in patients with
PSA-DT < 3 months and 23/33 events (70%) were in pa-
tients with PSA-DT less than 9 months. For PCD, 4/15
events were in patients with PSA-DT < 3 months and 12/
15 events were in the patients with PSA-DT less than
9 months.15 patients died of PC leaving 43/58 (74%) patients to
have died of other causes at a mean time of 76 months
after RP.Impact of surgical center
Patients had their RP at one of three hospitals: UNN (n =
248, St.Olav (n = 228) and NLSB (n = 59). There was no
statistical significant differences in risk of CF (p = 0.40)
and PCD (p = 0.973) between the centers.
Figure 2 Kaplan-Meier curves of patients experiencing biochemical failure for (A) Clinical failure free-survival stratified by
PSA-doubling time categories and (B) Prostate cancer death free-survival stratified by PSA-doubling time. See Table 3 for details
regarding hazard levels and level of significance.
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This is the first large Scandinavian multicenter study
presenting the impact of prognostic variable information
regarding BF, CF and PCD in Scandinavia in the PSAera. We found post RP PSA-DT to be a strong predictor
of CF and PCD, even outperforming Gleason score. In
addition we found PNI to be an independently strong
predictor of all event-free survivals. Otherwise we found
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sistent to previously published larger series [34-36].
The strength of this paper is the unselected study popu-
lation from Central and Northern Norway. It is reasonable
to assess that more than 95% of men diagnosed with PC
in this geographical area, were operated in hospitals that
participated in this study. Moreover, the study has a rela-
tively long FU, only patients in the PSA era were included,
all tissues have been re-evaluated by two experienced pa-
thologists, few patients had missing PSA-DT information,
we have included relevant prognostic factors, and adjuvant
treatment after RP was rare in the timeframe of this study.
Weaknesses of the study are the retrospective design, the
probable impact of salvage radiotherapy on the risk of
time to events and events are low at longer follow-up
times, contributing to low precision and large CIs (Tables 2
and 3). In addition, a number of tissue blocks were miss-
ing from one center, thereby reducing representativity.
Like other studies, we have found that the time from RP
to CF and death of PC to be extensive, even in patients
with a BF [21,37]. Prognostic factors to stratify patients for
risk-adapted follow-up, treatment regimens or clinical tri-
als are crucial since the majority of operated patients will
not have BF. Furthermore an even greater majority will
not experience symptoms of their disease and only a very
few will die of PC. On the other hand, it will be important
to identify those patients who otherwise will have symp-
toms from the recurrent disease or die. Another interest-
ing observation is that the involved surgeons seem very
capable to select patients for surgery with a long expected
survival as only 8% patients died of other causes during
follow up.
Our observation of post-prostatectomy PSA-DT as the
strongest predictor of CF and PCD in patients with BF is
consistent with numerous other studies recognizing the
importance of PSA-DT as a predictor of CF [21,22,38] and
PCD [37,39,40] after RP. We found the same pattern in
both health regions, thereby internally validating these re-
sults. The importance of PSA-DT in patients treated with
radiotherapy has also been reported [41]. In accordance
with Antonarakis et al. we found patients in the two low-
est PSA-DT categories (<3 months and 3–8,9 months) to
have the worst prognosis with comparable Hazards ratios
in the multivariable analysis. 64% of CF events and 80% of
PCD deaths were in these two groups even though they
collectively constituted only around 1/3 of the patients
(35%). Although there was a correlation between Gleason
Score and PSA-DT we saw the same trends of poor event-
free survival when stratified for Gleason Score subgroups,
but numbers were statistically insignificant due to the low
number of patients in each subgroup. Our observation
adds weight and validates the importance of PSA-DT for
selecting BF-patients at high risk of developing clinically
significant disease in the future.At time of diagnosis, Gleason score has been shown to be
a strong predictor of high risk PC [42], but also metastasis
and PCD after RP [38,43]. Including all patients in the ana-
lyses we consistently found patients with a Gleason sum ≥9
to have the highest risk of BF (equal to pT3b), CF and PCD.
This highlights a major impact of Gleason score in risk
stratification following RP. Some have, however, suggested
that Gleason score loses its value after including PSA-DT in
the risk-stratification [44]. Analyzing patients with BF only,
the PSA-DT removed Gleason score from the step-wise
multivariate analyses due to its co-variation and prognostic
strength. Antonarakis et al. found both Gleason score and
PSA-DT to contribute to estimate metastasis free-survival
[21] although PSA-DT was the strongest predictor.
Herein, extraprostatic PNI was in addition to Gleason
score the only clinicopathological variable to predict both
CF and PCD. Patients with an observed extraprostatic PNI
had estimated HRs of CF and PCD at around 3. The abil-
ity of PNI to predict subsequent events has been contro-
versial. Some have found PNI to independently predict BF
[45-48] while others did not found PNI to be a predictive
factor for any event [49-53]. D’Amico et al. reported PNI
to be an independent predictor of BF, but only for low risk
PC after evaluating biopsies [54]. Besides, the evaluation
of its role as a prognostic factor has been hampered as it
does not seem to be included as a histopathological vari-
able in the large series of the world e.g. the Johns Hopkins
database [55]. Most studies have only addressed the cor-
relation between PNI and BF and not the more clinical
relevant endpoints of CF and PCD. In the small, but inter-
esting study by Aumayr et al. reported that a high amount
of extraprostatic nerve infiltration correlated with tumor
progression [45]. PNI found in preoperative biopsies, has
also been found to be a predictor of metastasis and PCD
in patients treated with dose-escalated radiotherapy [56].
Our finding of extraprostatic PNI as independently signifi-
cant for prognosis with respect to CF and PCD, but not
for BF, is in accordance with these findings.
PSM rates in our material are high (overall 53%) and
among the highest that have seen published. In a large
published single-center series from Mayo by Boorjian
et al. in an almost identical period of time they found a
PSM rate of 31.1% with an decreasing incidence over time
[57]. The explanation could be the high incidence of pT3x
cancers (30%) compared to 12% in the Mayo cohort and
higher Gleason grades in our material, as these are inde-
pendent predictors of PSM. In addition, as our centers
during this timeframe were low-volume centers by inter-
national standards, this may have contributed to the high
PSM rates [58]. Refinement of surgical technique and
stage migration has been documented to improve the his-
topatological outcomes [59,60]. Margin location was rele-
vant in our cohort, as non-apical PSM were associated
with a poor BFFS and CFFS. Margin localization was not
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institution by Blute et al., they found PSM at the prostate
base to be independently associated to outcome, as did
Obek et al. [61,62]. A study by Godoy et al. found the base
and anterior localization of PSM to be independently asso-
ciated to an increased risk of BF compared to the other
margin localizations. They specifically advocate that there
is over-reporting of PSM from the apex and that an obser-
vation strategy is to be adopted for the large group of pa-
tients with a apical localization of PSM [63]. A Danish
study also found non-apical PSM to be independently as-
sociated to BF, whereas apical margins were insignificantly
associated to BF in multivariate analysis [64].
Conclusions
In conclusion, for the minority of patients with a subse-
quent BF we found a low PSA-DT to be the strongest
prognosticator for CF and PCD, recognizing its superiority
in risk-stratification in this subgroup. We also re-launch
PNI in the pathological specimen as a possible strong pre-
dictor of CF and PCD following RP and a thorough evalu-
ation in larger patient series is warranted.
As most patients, even after risk-stratification, will not
experience a clinically significant relapse of the disease we
need new prognostic markers to identify the relevant sub-
groups. We have included tissues from tumor and stroma
of these thoroughly described and largely unselected pa-
tients in tissue micro array blocks. Hence, this forms an
excellent platform for future molecular studies which will
hopefully give us some of these answers.
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